{"id":29396,"date":"2025-08-11T12:35:30","date_gmt":"2025-08-11T19:35:30","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/can-glp-1-drugs-treat-osteoarthritis-copy"},"modified":"2025-11-06T13:21:50","modified_gmt":"2025-11-06T21:21:50","slug":"microdosing-glp-1-as-a-new-weight-loss-trend","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/microdosing-glp-1-as-a-new-weight-loss-trend","title":{"rendered":"Microdosing GLP-1 as a New Weight Loss Trend"},"content":{"rendered":"

In the ever-evolving world of weight loss strategies, a new trend has emerged: microdosing GLP-1<\/a>. This approach to using popular weight loss medications like Zepbound and Wegovy has gained attention for its potential to offer benefits while minimizing side effects. But what exactly is GLP-1 microdosing, and is it a safe and effective way to manage weight?<\/p>\n

Active Ingredient: Semaglutide<\/h4>\n

Semaglutide is a GLP-1 receptor agonist only. It mimics the hormone GLP-1, which helps regulate blood sugar and appetite.<\/p>\n

\n
\n\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Ozempic<\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes; Cardiovascular risk reduction<\/td>\n2017<\/td>\n<\/tr>\n
Wegovy<\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2021<\/td>\n<\/tr>\n
Rybelsus<\/td>\nNovo Nordisk<\/td>\nOral (daily tablet)<\/td>\nType 2 diabetes<\/td>\n2019<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Throughout this article, any reference to semaglutide for weight loss refers to Wegovy. Mentions of semaglutide for blood sugar control refer to Ozempic.<\/div>\n<\/div>\n<\/div>\n

Active Ingredient: Tirzepatide<\/h4>\n

Tirzepatide is a dual agonist \u2014 it activates GLP-1 receptors and<\/em> GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP activity may enhance weight loss and blood sugar control compared to GLP-1\u2013only drugs.<\/p>\n

\n
\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Mounjaro<\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes<\/td>\n2022<\/td>\n<\/tr>\n
Zepbound<\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Throughout this article, any reference to Tirzepatide for weight loss refers to Zepbound. Mentions of Tirzepatide for blood sugar control refer to Mounjaro.<\/p>\n<\/div>\n<\/div>\n

Key takeaways<\/h2>\n